Story

Hims & Hers Stock Slips on Pre-Earnings Caution and Analyst Concerns

ENTHMSVIIDZHZH-TWJAKOHI
Aug 10, 20262 min read
Hims & Hers Stock Slips on Pre-Earnings Caution and Analyst Concerns
Text size
Background

Shares of Hims & Hers Health, Inc. (NYSE: HIMS) declined in pre-market trading Monday as investors reduced their positions ahead of the company's second-quarter 2026 earnings report, which is scheduled for release after the market close.

The stock fell 1.5% to $31.12 in pre-open activity, giving back a portion of the 6.5% gain it recorded in the prior session in a move attributed to pre-earnings profit-taking.

Analyst Caution and Slowing Growth Signals

Adding to the cautious tone, Truist Securities reiterated a Hold rating on Hims & Hers with a $27 price target, a significant discount to the stock's recent trading levels. The firm's analysis pointed to potential headwinds in a key growth area for the telehealth company.

According to Truist's proprietary card data, billings for GLP-1 weight-loss drugs declined by 1% month-over-month in July. This marks a notable slowdown after a robust 32% month-over-month jump in June, raising questions among investors about the sustainability of that momentum.

Earnings Expectations and Legal Headwinds

Sample IUX Markets – In-articleAd

Analysts broadly expect Hims & Hers to report a net loss for the second quarter, a reversal from the profit it posted in the same period a year ago.

  • Earnings Per Share (EPS): Consensus estimates forecast a loss of approximately $0.05 per share, compared to a profit of $0.17 per share in Q2 2025.
  • Revenue: The consensus revenue estimate is near $730 million.
  • Implied Volatility: Options markets have priced in a potential post-earnings stock swing of roughly 14.5% in either direction, according to Investing.com.

The company also continues to face legal and regulatory scrutiny. In late July, the Federal Trade Commission (FTC) filed a lawsuit alleging Hims & Hers shared sensitive user health data with third-party advertising platforms. This legal overhang, along with separate investigations by law firms over alleged securities violations, has weighed on investor sentiment.

The upcoming earnings report and management's outlook will be a critical test for the stock's direction, balancing bullish long-term views on its product pipeline against these near-term concerns.

Read next

More on Stocks
Back to latest news

LATEST